Table 3. Level of asthma symptom control and severe exacerbation across SABA inhaler prescription categories in the Malaysian cohort of SABINA III.
|
SABA prescriptions in the previous 12 months |
|||
|---|---|---|---|
|
1–2 inhalers |
>3 inhalers |
Total |
|
|
Level of asthma symptom control, n (%) | |||
|
Patients with uncontrolled asthma |
24 (12.9) |
80 (24.7) |
114 (19.4) |
|
Patients with at least partly controlled asthma* |
230 (87.1) |
244 (75.3) |
474 (80.6) |
|
Total |
264 |
324 |
588 |
|
Patients with at least one severe exacerbation in the previous 12 months, n (%) | |||
|
≥1 exacerbation |
115 (43.6) |
196 (60.5) |
311 (52.9) |
|
0 exacerbations |
149 (56.4) |
128 (39.5) |
277 (4.1) |
|
Total |
264 |
324 |
58 |
SABA, short-acting β2-agonist; SABINA, SABA use IN Asthma.
*
At least partly controlled asthma was defined as partly controlled plus well-controlled asthma.